Why Clinical Success Does Not Guarantee Commercial Success?

A therapy can succeed in clinical trials and still fail in the market. For biotechnology companies and investors, this distinction is critical.

Clinical success answers an important question: Does the therapy provide sufficient evidence of safety and efficacy? Commercial success asks a much broader set of questions. Is the improvement meaningful compared with existing treatments? Will physicians prescribe it? Will patients accept it? Will insurers pay for it? Can the company manufacture and distribute it profitably?

These questions become especially important when several therapies compete for the same patients. A product may receive regulatory approval but struggle because competitors offer greater convenience, lower cost, better safety, stronger efficacy, or earlier market entry. Commercialization also introduces risks that clinical trials cannot fully resolve. Manufacturing capacity, pricing, reimbursement, supply chains, physician behavior, patient access, intellectual property, and competitive responses can all reshape the value of an approved therapy.

This is why biotechnology evaluation should not stop at predicting clinical success. Market Translation Prediction™ extends the analysis toward the probability that clinical value can be converted into adoption, revenue, and sustainable market position. The ultimate question is not simply: Will the therapy work? It is: If it works, will the market reward it?

If you would like to access a comprehensive analysis report on “Market Translation Prediction™,” please visit my in-depth publications at

AASE | Predictive Success Science (https://substack.com/@jackhuang2026).